ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Microneedle-Based Biofuel Cell with MXene/CNT Hybrid Bioanode: Fundamental and Biomedical Application.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in electrical stimulation-based therapeutic technologies for sarcopenia prevention and treatment.Bioactive materials · 2026Review
- Microneedle Technologies for Drug Delivery: Innovations, Applications, and Commercial Challenges.Micromachines · 2026Review
- Microneedle-Based Biofuel Cell with MXene/CNT Hybrid Bioanode: Fundamental and Biomedical Application.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Biofuel cells show emerging potential as energy-supply platform by harvesting bioenergy from human biofluids for next-generation self-powered transdermal drug delivery systems. Herein, the study proposes the hydrogel-based microneedle patch as the drug penetration unit within the corneum to drive the large drug molecules' delivery. Benefiting from the high porosity and swelling capability, the interstitial fluid can be extracted efficiently to the body surface. One biofuel cell is integrated into the microneedle patch with MXene/carbon nanotube functionalized glucose oxidase bioanode. The transdermal currents of 4-5 µA and open-circuit potential of 0.28 V are collected in in vivo. The transdermal delivery efficiency and releasing rate of ciprofloxacin and insulin are significantly enhanced in vitro and in vivo models, respectively. The theoretical simulations provide detailed insights into the good electron transport and substrate adsorption, glucose replenishment, and drug delivery under electric field, benefiting the development of transdermal drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.